Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer

Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer

US Patent 10940127 · Granted Mar 9, 2021

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Treatment of diseases by concurrently eliciting remyelination effects and immuno2025
Autoimmune disorder treatment using RXR agonists2023
RAR selective agonists in combination with immune modulators for cancer immunoth2023
Receptor subtype and function selective retinoid and rexinoid compounds in combi2023
Immunomodulatory and differentiating function selective retinoid and rexinoid co2023
Treatment of autoimmune diseases with combinations of RXR agonists and thyroid h2023
Treatment of autoimmune diseases with combinations of RXR agonists and thyroid h2023
Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer2023
Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer2023
Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer2023
Receptor subtype and function selective retinoid and rexinoid compounds in combi2023
Autoimmune disorder treatment using RXR agonists2023